Stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma: imaging evaluation post treatment.

Surgical resection, when feasible, is the standard of care for hepatocellular carcinoma. However, many tumours are not resectable at the time of diagnosis. Recently, stereotactic body radiation therapy (SBRT) has emerged as a non-invasive local therapy for both non-resectable primary hepatic malignancies as well as hepatic metastases. Knowledge of the expected hepatic parenchymal appearance post treatment, as well as potential pitfalls and complications, is essential for accurate evaluation of treatment response. This pictorial review provides a fundamental description of the SBRT technique, outlines the expected cross-sectional imaging appearances of tumour response, and highlights potential pitfalls in interpretation. The expected liver parenchymal changes post-SBRT are also reviewed, along with some common radiation-induced complications.

[1]  J. Salleron,et al.  Tumor response assessment by MRI following stereotactic body radiation therapy for hepatocellular carcinoma , 2017, PloS one.

[2]  K. Sandrasegaran,et al.  Three-Dimensional Conformal Radiation Therapy in the Liver: MRI Findings Along a Time Continuum , 2015, Journal of computer assisted tomography.

[3]  Tomas Kron,et al.  CT perfusion imaging in response assessment of pulmonary metastases undergoing stereotactic ablative radiotherapy , 2015, Journal of medical imaging and radiation oncology.

[4]  Andrew X. Zhu,et al.  Radiation therapy for liver tumors: ready for inclusion in guidelines? , 2014, The oncologist.

[5]  S. Park,et al.  Stereotactic Body Radiotherapy-Induced Arterial Hypervascularity of Non-Tumorous Hepatic Parenchyma in Patients with Hepatocellular Carcinoma: Potential Pitfalls in Tumor Response Evaluation on Multiphase Computed Tomography , 2014, PloS one.

[6]  William Y. Song,et al.  Stereotactic body radiation therapy for primary hepatic malignancies and metastases to liver: a technical and literature review , 2013 .

[7]  Meei-Shyuan Lee,et al.  18F-FDG PET and Combined 18F-FDG–Contrast CT Parameters as Predictors of Tumor Control for Hepatocellular Carcinoma After Stereotactic Ablative Radiotherapy , 2013, The Journal of Nuclear Medicine.

[8]  S. Perkins,et al.  Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma , 2012, Cancer.

[9]  Jimmy J Caudell,et al.  Stereotactic body radiation therapy for liver metastases and primary hepatocellular carcinoma: normal tissue tolerances and toxicity. , 2010, Cancer control : journal of the Moffitt Cancer Center.

[10]  Riccardo Lencioni,et al.  Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.

[11]  N. Burnet,et al.  Defining the tumour and target volumes for radiotherapy , 2004, Cancer imaging : the official publication of the International Cancer Imaging Society.

[12]  M. Laeeq Khan,et al.  Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. , 2000, Journal of hepatology.

[13]  W. Alexander,et al.  European Association for the Study of the Liver , 1968 .

[14]  V. Mazzaferro,et al.  EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer , 2012 .